Chemotherapy for early-stage breast cancer: the more the better?
[...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the pref...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2023-04, Vol.401 (10384), p.1243-1245 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1245 |
|---|---|
| container_issue | 10384 |
| container_start_page | 1243 |
| container_title | The Lancet (British edition) |
| container_volume | 401 |
| creator | Shen, Song-Jie Liu, Chang-Mei |
| description | [...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the preferred regimen to achieve optimum survival benefit, with similar proportional reductions irrespective of patient age or tumour characteristics, including size, grade, nodal involvement, hormone receptor status, or HER2 expression. |
| doi_str_mv | 10.1016/S0140-6736(23)00094-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2801981373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673623000946</els_id><sourcerecordid>2801981373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-2c2210769b5f98106a00249a4f2078c681ba5e09e4160578b6ad6a7c2aeb66f73</originalsourceid><addsrcrecordid>eNqFkMtKAzEUQIMotj4-QRlwUxejN49JZtxUKb6g4EIFdyGTuWOnzHRqMhX696YPu3AjBJLFuSeXQ8gZhSsKVF6_AhUQS8XlgPFLAMhELPdInwol4kSoj33S3yE9cuT9NEBCQnJIelyBpCyRfXI7mmDTdhN0Zr6MytZFaFy9jH1nPjHKHRrfRdbMLLqbKGBR0zpcP3LsOnTDE3JQmtrj6fY-Ju8P92-jp3j88vg8uhvHlme8i5lljIKSWZ6UWUpBGgAmMiNKBiq1MqW5SRAyFDSsqNJcmkIaZZnBXMpS8WMy2Hjnrv1aoO90U3mLdW1m2C68ZinQIOaKB_TiDzptF24WtltRwR7OSphsKOta7x2Weu6qxrilpqBXifU6sV7104zrdWItw9z51r7IGyx2U79NAzDcABhyfFfotLcVhoJF5dB2umirf774AWIIiF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2800570577</pqid></control><display><type>article</type><title>Chemotherapy for early-stage breast cancer: the more the better?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Shen, Song-Jie ; Liu, Chang-Mei</creator><creatorcontrib>Shen, Song-Jie ; Liu, Chang-Mei</creatorcontrib><description>[...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the preferred regimen to achieve optimum survival benefit, with similar proportional reductions irrespective of patient age or tumour characteristics, including size, grade, nodal involvement, hormone receptor status, or HER2 expression.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(23)00094-6</identifier><identifier>PMID: 37061256</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anthracycline ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biopsy ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Clinical trials ; Collaboration ; Endocrine therapy ; ErbB-2 protein ; Female ; Humans ; Lymphatic system ; Meta-analysis ; Mortality ; Neoplasm Staging ; Patients ; Surgery ; Toxicity ; Tumors ; Womens health</subject><ispartof>The Lancet (British edition), 2023-04, Vol.401 (10384), p.1243-1245</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-2c2210769b5f98106a00249a4f2078c681ba5e09e4160578b6ad6a7c2aeb66f73</citedby><cites>FETCH-LOGICAL-c393t-2c2210769b5f98106a00249a4f2078c681ba5e09e4160578b6ad6a7c2aeb66f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673623000946$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37061256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Song-Jie</creatorcontrib><creatorcontrib>Liu, Chang-Mei</creatorcontrib><title>Chemotherapy for early-stage breast cancer: the more the better?</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>[...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the preferred regimen to achieve optimum survival benefit, with similar proportional reductions irrespective of patient age or tumour characteristics, including size, grade, nodal involvement, hormone receptor status, or HER2 expression.</description><subject>Anthracycline</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>Endocrine therapy</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphatic system</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Surgery</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Womens health</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkMtKAzEUQIMotj4-QRlwUxejN49JZtxUKb6g4EIFdyGTuWOnzHRqMhX696YPu3AjBJLFuSeXQ8gZhSsKVF6_AhUQS8XlgPFLAMhELPdInwol4kSoj33S3yE9cuT9NEBCQnJIelyBpCyRfXI7mmDTdhN0Zr6MytZFaFy9jH1nPjHKHRrfRdbMLLqbKGBR0zpcP3LsOnTDE3JQmtrj6fY-Ju8P92-jp3j88vg8uhvHlme8i5lljIKSWZ6UWUpBGgAmMiNKBiq1MqW5SRAyFDSsqNJcmkIaZZnBXMpS8WMy2Hjnrv1aoO90U3mLdW1m2C68ZinQIOaKB_TiDzptF24WtltRwR7OSphsKOta7x2Weu6qxrilpqBXifU6sV7104zrdWItw9z51r7IGyx2U79NAzDcABhyfFfotLcVhoJF5dB2umirf774AWIIiF4</recordid><startdate>20230415</startdate><enddate>20230415</enddate><creator>Shen, Song-Jie</creator><creator>Liu, Chang-Mei</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20230415</creationdate><title>Chemotherapy for early-stage breast cancer: the more the better?</title><author>Shen, Song-Jie ; Liu, Chang-Mei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-2c2210769b5f98106a00249a4f2078c681ba5e09e4160578b6ad6a7c2aeb66f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anthracycline</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>Endocrine therapy</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphatic system</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Surgery</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Song-Jie</creatorcontrib><creatorcontrib>Liu, Chang-Mei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Song-Jie</au><au>Liu, Chang-Mei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy for early-stage breast cancer: the more the better?</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2023-04-15</date><risdate>2023</risdate><volume>401</volume><issue>10384</issue><spage>1243</spage><epage>1245</epage><pages>1243-1245</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>[...]these results, based on comparing a range of trials, should be interpreted with caution. [...]the balance of benefit versus toxicity needs to be considered carefully for escalation in chemotherapy. According to the results, concurrent taxane and anthracycline for six cycles seems to be the preferred regimen to achieve optimum survival benefit, with similar proportional reductions irrespective of patient age or tumour characteristics, including size, grade, nodal involvement, hormone receptor status, or HER2 expression.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37061256</pmid><doi>10.1016/S0140-6736(23)00094-6</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2023-04, Vol.401 (10384), p.1243-1245 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2801981373 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anthracycline Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Chemotherapy Chemotherapy, Adjuvant Clinical trials Collaboration Endocrine therapy ErbB-2 protein Female Humans Lymphatic system Meta-analysis Mortality Neoplasm Staging Patients Surgery Toxicity Tumors Womens health |
| title | Chemotherapy for early-stage breast cancer: the more the better? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A58%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy%20for%20early-stage%20breast%20cancer:%20the%20more%20the%20better?&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Shen,%20Song-Jie&rft.date=2023-04-15&rft.volume=401&rft.issue=10384&rft.spage=1243&rft.epage=1245&rft.pages=1243-1245&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(23)00094-6&rft_dat=%3Cproquest_cross%3E2801981373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2800570577&rft_id=info:pmid/37061256&rft_els_id=S0140673623000946&rfr_iscdi=true |